Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 9/20 | 0.48 |
| ▸ | BRAF | P15056 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.43 |
| ▸ | DHFR | P00374 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 2/20 | 0.43 |
| ▸ | FLT1 | P17948 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4072496 | 0.81 | BRAF (0.47) | EGFRBRAFMAPTTP53ERBB2 | |
| SCHEMBL13620919 | 0.81 | MAPK1 (0.64) | MAPK1EGFRMAPTTP53ERBB2 | |
| SCHEMBL4064191 | 0.78 | SYK (0.46) | MAPK1EGFRMAPTTP53ERBB2 | |
| SCHEMBL14992584 | 0.74 | MAPT (0.69) | EGFRMAPTTP53ERBB2ABCB1 | |
| SCHEMBL12065998 | 0.72 | EGFR (0.52) | MAPK1EGFRMAPTTP53ERBB2 | |
| SCHEMBL4062147 | 0.72 | EGFR (0.61) | MAPK1EGFRBRAFMAPTERBB2 | |
| SCHEMBL17022105 | 0.71 | PIK3CA (0.55) | MAPK1MAPTAURKADHFRKDR | |
| SCHEMBL13631917 | 0.70 | EGFR (0.53) | MAPK1EGFRMAPTTP53ERBB2 | |
| SCHEMBL12227606 | 0.68 | EGFR (0.51) | MAPK1EGFRBRAFMAPTTP53 | |
| SCHEMBL30163053 | 0.68 | EGFR (0.51) | MAPK1EGFRBRAFMAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1851217-B1 | SUBSTITUTED PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES USEFUL AS MEDICINES FOR THE TREATMENT OF AUTOIMMUNE DISORDERS | 4 AZA IP NV (BE) | 2009-02-11 | — | — | EP | claimed |
| US-20080312227-A1 | Substituted Pyrido(2,3-D) Pyrimidine Derivatives Useful as Medicines for the Treatment of Autoimmune Disorders | 4 AZA BIOSCIENCE NV (BE) | 2008-12-18 | — | — | US | claimed |
| EP-1851217-A1 | SUBSTITUTED PYRIDO(2,3-D)PYRIMIDINE DERIVATIVES USEFUL AS MEDICINES FOR THE TREATMENT OF AUTOIMMUNE DISORDERS | 4 AZA IP NV (BE) | 2007-11-07 | — | — | EP | claimed |
| WO-2006087229-A1 | SUBSTITUTED PYRIDO (2 , 3-D) PYRIMIDINE DERIVATIVES USEFUL AS MEDICINES FOR THE TREATMENT OF AUTOIMMUNE DISORDERS | 4 AZA IP NV (BE) | 2006-08-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312227-A1 | Substituted Pyrido(2,3-D) Pyrimidine Derivatives Useful as Medicines for the Treatment of Autoimmune Disorders | PNPO, TPMT, TNF | MAPK1 1351/4885EGFR 3613/4885BRAF 775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.